吡喹酮治疗血吸虫病肝纤维化的临床研究

Clinical Research of Praziquantel in the Treatment of Hepatic Fibrosis of Schistosomiasis

目的:探讨吡喹酮治疗血吸虫病肝纤维化的疗效。方法:选取本院2015年3月-2016年1月,确诊的120例血吸虫病肝纤维化患者,按照随机数字表法分为治疗组和对照组,每组60例,双盲法观察各组治疗前后的肝脏B超变化、血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层黏连蛋白(LN)、Ⅳ型胶原(CL-Ⅳ)、间质金属蛋白酶(MMPS)、间质金属蛋白酶抑制因子(TIMPS)及转化生长因子β1(TGF-β1)的变化。结果:治疗组治疗后HA、CL-Ⅳ、PC-Ⅲ、LN、TIMP1、TIMP2及TGF-β1明显降低,而MMP2和MMP9上升,比较差异均有统计学意义(P<0.05);对照组治疗前后比较,差异均无统计学意义(P>0.05);肝脏B超检查积分治疗组的下降率明显低于对照组,比较差异有统计学意义(P<0.05)。结论:吡喹酮治疗血吸虫病肝纤维化疗效较好。

Objective： To explore the effect of Praziquantel in the treatment of hepatic fibrosis of schistosomiasis.Method： From March 2015 to January 2016, 120 patients with hepatic fibrosis of schistosomiasis in our hospital were randomly divided into the treatment group （ 60 cases ） and the control group （ 60 cases ） . Changes of liver B ultrasonic, serum hyaluronic acid （ HA ）, procollagen type Ⅲ （ PC-Ⅲ ）, laminin （ LN ）, collagen type Ⅳ （ CL-Ⅳ）, matrix metalloproteinases （ MMPS ）, tissue inhibitor of metalloproteinases （ TIMPS ） and TGF-β 1 of two groups were observed.Result： After treatment, HA, CL-Ⅳ, PC-Ⅲ, LN, TIMP1 and TIMP2 and TGF- β 1 of the treatment group significantly decreased, MMP2 and MMP9 rose, the differences were statistically significant （ P〈0.05 ） .The liver B integral decline rate of the treatment group was obviously lower than that of the control group, the difference was statistically significant （ P〈0.05 ） .Conclusion： The effect of Praziquantel in the treatment of hepatic fibrosis of schistosomiasis is satisfactory.